Methicol

Quick links to important sections

Methicol

Treatment option:

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Methicol

What is Methicol? Defining the Core Substance

Property Description
Active ingredient Mecobalamin (Methylcobalamin)
Form Tablet (Oral), Injection (Parenteral Solution)
Pharmacological class Vitamin B₁₂ Analogue (ATC B03BA)
General purpose Neurological support and Metabolic balance
Origin Derived synthetic form

Methicol is a medicinal preparation whose primary component is the active ingredient Mecobalamin (Methylcobalamin), a specific, biologically active form of Vitamin B₁₂ (Cobalamin). This compound is classified within the high-level pharmacological group of Antianemic preparations, specifically the B₁₂ analogues (ATC B03BA). Mecobalamin is defined by its structure as the methylated form, which is structurally identical to the Cobalamin coenzyme naturally utilized within the human body. This distinction is recognized for its efficiency in addressing conditions requiring direct B₁₂ intervention.


Mecobalamin: The Activated B₁₂ Form and Composition

The crucial chemical distinction of Mecobalamin is its status as the biologically active form, meaning the body can use it directly without the preliminary metabolic conversion steps required by inactive precursors like Cyanocobalamin. This means the body receives an immediately usable nutrient source to support nerve function. Methicol is formulated as a single active ingredient product, available in different pharmaceutical forms, including oral tablet forms (often sublingual or disintegrating) and an aqueous solution in ampoules for parenteral injection. The brand Methicol is often positioned for adult use, emphasizing the direct action of the active coenzyme, which is key for its neuro-active effects.


What is the General Purpose of Methicol?

The general purpose of Methicol is to efficiently supplement the body with this readily usable Cobalamin form to maintain neurological integrity and support essential metabolic functions. Mecobalamin is effective as a critical methyl donor, providing the necessary chemical group for fundamental enzymatic reactions, and is recognized as a neuro-active substance. Its utility therefore centers on offering foundational support to the central and peripheral nervous system and aiding metabolic pathways, including those crucial for red blood cell formation. Cobalamin is vital for maintaining nerve cell health and ensuring DNA synthesis. This role underscores the necessity of this coenzyme for fundamental cellular maintenance.

Regulatory References

  1. World Health Organization (WHO) website

What side effects are possible with Methicol?

Possible Side Effects and Safety Information

The safety profile of Methicol (Mecobalamin) is formally documented by regulatory authorities, classifying potential adverse reactions by both frequency and the physiological system affected. Most documented effects are generally non-serious and involve the Gastrointestinal System or the Skin and Subcutaneous Tissue.


Documented Adverse Reactions by System

System-Organ Class Officially Listed Effects
Gastrointestinal Anorexia, nausea, vomiting, diarrhea.
Skin & Immune System Rash, itching, and general signs of hypersensitivity.
Nervous System Headache.

Serious Safety Considerations

Regulatory documents emphasize that while rare, serious adverse reactions have been documented with B12 analogues. These include severe Allergic Reactions (such as anaphylactic shock) and specific Cardiovascular Events, including reports of Congestive Heart Failure and Peripheral Vascular Thrombosis (blood clots)

. Furthermore, the official labeling notes the possibility of Hypokalemia (low potassium levels) during the initial, intense treatment phase of severe megaloblastic anemia.

Restrictions and Special Populations

The medicine is contraindicated (should not be used) in individuals with known hypersensitivity to Mecobalamin or any component of the formulation. It is also explicitly contraindicated for patients with early-stage Leber's hereditary optic atrophy. Cautions are also noted for use in patients with a history of severe liver disease or renal impairment, where clinical consideration may be required. Older adults may also experience reduced intestinal absorption of the substance.

Overdose and Emergency Response

Overdose and when to seek help

The official regulatory classification for Methicol (Mecobalamin) indicates a low acute toxicity and a wide therapeutic margin. Therefore, acute overexposure to the medicine is generally well-tolerated, and no specific severe symptoms or intoxication syndrome is officially documented in prescribing information.

Overdose Scope and Manifestations

Official labeling confirms that the physiological response to excessive intake involves the compound’s water-soluble nature, resulting in the rapid and substantial renal excretion of the surplus Mecobalamin. Due to this efficient elimination and inherent low risk, no detrimental effects on major organ systems are explicitly listed as an outcome of overdose. Population-specific overdose risks are not documented.

Emergency Response and Management

The standard regulatory guidance mandates that no specific antidote is known for Mecobalamin overdose. Consequently, treatment is strictly defined as symptomatic and supportive, aiming to manage any rare, transient symptoms that may occur.

When Immediate Medical Help is Required

While routine intensive monitoring is generally not required, official regulatory phrasing advises that medical advice should be sought for the observation of any unexpected or persistent adverse reactions. However, due to the low-risk profile, immediate emergency attention is not mandated by regulators solely for isolated Mecobalamin overexposure.

Therapeutic Uses of Methicol

What Methicol Treats: Main Uses and Benefits

Methicol is a common brand name for Methylcobalamin, an active coenzyme form of Vitamin B12. This medicine is generally used for managing symptoms related to systemic imbalance and neurological conditions. The therapeutic role of Methicol is aligned with official uses for Methylcobalamin, which is relevant in managing certain conditions. This includes relevance for easing symptoms that may become intense or disruptive, such as those associated with Peripheral Neuropathy and Megaloblastic Anemia.

The supportive effect is relevant in clinical settings that involve acute or unstable symptom patterns, and assists with managing groups of symptoms that may appear suddenly or fluctuate. It is relevant for easing symptoms that interfere with daily comfort, including physical discomfort, tingling, and numbness.

“Methicol provides support across therapeutic domains where short-term symptomatic assistance is appropriate, contributing to improved comfort during difficult episodes.”

Methicol is commonly used to address symptom clusters associated with conditions involving increased neurological activity (such as peripheral neuropathies) and symptoms related to systemic imbalance (such as megaloblastic anemia).

Quick Fact: Supports Easing Physical Discomfort

Regulatory References

  1. FDA Verification Portal

Eligibility and Restrictions for Use

Who can and cannot use Methicol?

Methicol (Methylcobalamin) eligibility is strictly determined by official regulatory documents, which define absolute prohibitions and use restrictions based on population and health status.

Contraindicated Populations

Methicol is formally contraindicated in patients with a known hypersensitivity to the active ingredient (Cobalamin) or cobalt. Use is also prohibited in individuals diagnosed with Leber's Disease (hereditary optic nerve atrophy). Certain injectable formulations are contraindicated in newborns and premature infants due to excipient safety warnings documented in the labeling.

Age-Related Eligibility

Use is established for adults and children aged 11 years and above. Conversely, safety and effectiveness have not been established in children below the age of 11 years.

Restricted and Conditional Use

Patients with pre-existing renal impairment or hepatic impairment are designated as populations for whom use is restricted or conditional, typically requiring specific clinical monitoring. Use during pregnancy is subject to restriction and often requires avoidance after the first trimester, and lactation is a restricted state for certain Methicol products.

What should I know about interactions with other medicines?

Methicol Interactions with other medicines and products

This section summarizes officially documented interactions for Methicol (Mecobalamin), based strictly on government regulatory documents.

Documented Interactions

The primary documented interactions involve substances that can interfere with the body's ability to absorb Mecobalamin or supplements that can mask underlying deficiency symptoms.

Type of Interaction Examples of Interacting Substances
Reduced Absorption Gastric acid inhibitors (e.g., Omeprazole, Cimetidine), Metformin, Neomycin, Aminosalicylic acid, Colchicine, and certain antibiotics are documented to potentially lower the body's absorption of Mecobalamin .
Symptom Masking Folic acid supplements are officially noted to mask the blood (hematological) signs of Megaloblastic Anemia caused by Vitamin B12 deficiency, which may allow associated neurological issues to progress unaddressed.

Other Official Cautions

Contraindicated Combinations: Regulatory documents do not list any specific drug-drug combinations that are formally classified as contraindicated with Methicol. The main contraindication is for individuals with Leber's disease or known hypersensitivity to cobalt or Mecobalamin.

Substance Use: Heavy or chronic intake of alcohol is documented to interfere with the intestinal absorption of Mecobalamin. Additionally, the regulatory profile notes that elderly individuals may naturally have a reduced capacity to absorb the active ingredient from the intestines.

Mechanism of Action

Methionine Synthase Cofactor and Metabolic Regeneration

Methicol, containing Mecobalamin, functions as an essential coenzyme for the enzyme Methionine Synthase (MTR). The mechanism requires Mecobalamin to donate its methyl group ( CH3) to regenerate MTR's activity, a process essential for the conversion of Homocysteine to Methionine. This metabolic recycling promotes the continuation of the primary biochemical cascade and sustains the production of the critical methyl donor, S-adenosylmethionine (SAM).


Neuro-Structural Support and Functional Modulation

By ensuring adequate SAM synthesis, the mechanism facilitates the methylation reactions necessary for the structural integrity and function of the nervous system. These reactions promote the building and maintenance of the myelin sheath and facilitate axonal regeneration. This structural mechanism contributes to the maintenance of optimal nerve signaling capability. Furthermore, Mecobalamin is utilized to maintain neuronal function, facilitating the stabilization of sensory fibers, and functioning to suppress ectopic spontaneous discharges within the peripheral nervous system.

Dosage and Administration Information

How to Use Methicol

Methicol (Mecobalamin) administration is governed by established guidelines, specifying two primary routes and distinct dosing schedules based on the course of treatment. The available pharmaceutical forms include Tablets for oral use and an Injection solution for parenteral delivery.


Official Administration Routes and Schedules

Route of Administration Standard Adult Dosing Frequency Pattern
Oral (Tablet) 1,500 mu g total daily dose. Typically three times a day in divided doses.
Parenteral (IM, SC) 500 mu g per administration. Initial Phase: Often daily or three times per week. Maintenance: Once monthly or less frequently.

Procedural and Contextual Instructions

Methicol is used under two distinct dosing models: a short-term, high-frequency loading phase via injection to establish circulating levels, followed by a low-frequency maintenance phase that sustains these levels. For the parenteral route, the injection is administered either intramuscularly (IM) or deep subcutaneously (SC). The injectable solution must be used promptly after opening and protected from light due to the photosensitivity of Mecobalamin.

Oral administration is generally permitted with or without food. Dosing for all forms may be adjusted according to the patient's age and the severity of symptoms, with caution advised for pediatric use. Prolonged administration is not recommended if there is no observed clinical response to the medicine.

Recent Clinical Evidence

Research evidence / Overview of studies for Methicol

Evidence for Use in Peripheral Neuropathy and Nerve Support

Research on Methicol (Mecobalamin) has been conducted in studies exploring how symptoms change over time in conditions characterized by fluctuating or episodic manifestations, such as peripheral neuropathy. Researchers have utilized Randomized Controlled Trials (RCTs) to examine patient-reported experiences related to outcomes of physical discomfort, including tingling, pain, and numbness. These trials were applied in research contexts involving unstable symptoms in adults with different forms of nerve damage, including those diagnosed with Diabetic Peripheral Neuropathy (DPN).

Studies report how symptoms evolved in the observed populations during the study period, often tracking measurements in validated scoring systems designed to examine symptom intensity. Findings describe patterns observed in the studies regarding measurements of both subjective reports of discomfort and objective variables related to nerve function (such as the speed of nerve signals). Findings were mixed, and the overall evidence base consists of several studies, but its consistency is impacted by various study designs used.

Evidence for Use in Megaloblastic Anemia and B₁₂ Deficiency

Research was conducted to explore the medicine's role as a Vitamin B₁₂ analogue for conditions marked by functional limitations and systemic imbalance, such as megaloblastic anemia resulting from B₁₂ deficiency. Research examined the medicine's role in addressing these deficiency states in adults through comparative RCTs and clinical reviews.

These studies monitored outcomes describing systemic or functional imbalance, such as the normalization of red blood cell counts and the reduction of certain metabolic markers like Homocysteine and Methylmalonic Acid (MMA). Findings indicate a consistent metabolic response, and the evidence base contributes to the broader understanding of deficiency correction and is aligned with established clinical consensus for B₁₂ replacement.

What is Still Uncertain About Methicol Research

The research highlights what is known—and what is still uncertain. Evidence quality varies across studies, particularly regarding the consistency of reported findings for peripheral neuropathy. Comparative evidence is lacking to fully clarify whether one form of B₁₂ (Mecobalamin) provides definitive advantages over others for correcting all deficiency-related symptoms. Data are still emerging for some specific populations, and long-term effects are not fully established for most indications, meaning the follow-up durations were limited. This research provides context but not individual predictions.

Frequently Asked Questions (FAQ)

Common questions about Methicol (FAQ)


Q: Can Methicol be taken by people with kidney issues?

A: Regulatory information indicates that Methicol is a form of B₁₂ generally considered in this population over other B₁₂ analogues. However, official labeling notes that its use in patients with any renal impairment is generally restricted or conditional and requires specific clinical monitoring.

Q: What happens if I miss a dose of Methicol?

A: If a dose is missed, standard instructions for pharmaceutical products often suggest taking the dose as soon as it is remembered. However, if it is close to the time of the next scheduled dose, the missed dose should be skipped entirely, and the regular schedule continued. Product information generally states that taking two doses to make up for a missed one is not recommended.

Q: Can older adults use Methicol?

A: Methicol is a medicine established for use in adults, including older individuals. However, regulatory documents note that older adults may naturally have a reduced capacity to absorb the active ingredient from the intestines compared to younger adults. This reduced absorption capacity is a factor that may be considered during treatment monitoring.

Q: Does Methicol interact with common pain relievers like ibuprofen?

A: Official drug interaction checkers for Mecobalamin (the active ingredient in Methicol) and common non-steroidal anti-inflammatory drugs (NSAIDs) like ibuprofen generally do not list a documented interaction. The absence of a documented interaction does not rule out all possibilities; informing a healthcare provider about all concurrent medicines remains a primary precaution.

Q: Does Methicol interact with blood thinners?

A: Official drug interaction databases for Mecobalamin (a B₁₂ analogue) and common oral blood thinners (anticoagulants) like warfarin generally do not list a documented interaction. B₁₂ analogues are generally not cited as being a primary concern for interacting with blood-thinning medication.

Q: Does Methicol interact with grapefruit?

A: Regulatory documents and interaction resources do not specifically list an interaction between Methicol and grapefruit. Mecobalamin is not primarily metabolized by the enzyme system commonly affected by grapefruit.

Q: Is it normal to have mild headaches when first starting Methicol?

A: Official regulatory documents list headache as one of the documented adverse reactions that can occur with Methicol. The product labeling generally confirms that headache is among the possible effects, but it does not specify if the effect is more likely during the initial phase of treatment.

Q: Are there any specific demographic groups where Methicol is studied more?

A: While the core purpose focuses on adults with megaloblastic anemia and peripheral neuropathy, clinical research records document studies in other specific populations outside of the core indications to understand the medicine's functional support.

Q: Does Methicol have any black box warnings?

A: Official Mecobalamin (Vitamin B₁₂) product labeling from major regulatory authorities generally does not include a Black Box Warning. The Black Box Warning is the highest safety warning mandated by the FDA for drugs with serious or life-threatening risks.

Q: Is Methicol considered a controlled substance?

A: Methicol (Mecobalamin) is chemically classified as a Vitamin B₁₂ analogue. This compound classification is not listed as a controlled substance by U.S. or international drug enforcement agencies and is not subject to the scheduling requirements for controlled substances.

Q: How long does Methicol typically take to start working?

A: Regulatory documents do not provide a specific timeframe for when symptomatic relief begins for patients. The medicine's active component has a documented half-life ranging from approximately 6 to 24 hours. Clinical response to treatment for nerve conditions or deficiency is often evaluated over a period of several weeks.

Q: Is it common to feel tired when starting Methicol?

A: General fatigue or tiredness is not typically listed among the most common adverse reactions in the official Mecobalamin product labeling. The official safety information focuses on effects like nausea, vomiting, rash, and headache.

Q: What should I do if I feel like Methicol isn't working for me?

A: The official documentation on the use of Methicol states that prolonged administration is not recommended if there is no observed clinical response to the medicine. This highlights the importance of regular clinical evaluation to determine if the treatment goal is being met.

Q: Is Methicol typically used in long-term treatment?

A: While the medicine may be used for long-term maintenance in deficiency states, the research overview indicates that long-term effects are not fully established for most indications. This means that the follow-up durations in formal clinical studies were limited.

Q: Can Methicol affect sleep patterns?

A: Specific changes to sleep patterns are not commonly listed in the regulatory adverse reactions profile for Mecobalamin. The effects on the nervous system listed in the labeling are primarily limited to the occurrence of headache.

Q: Does Methicol cause weight gain or loss?

A: Weight changes (gain or loss) are not typically listed in the regulatory adverse reactions profile for Methicol. The most common gastrointestinal effect listed in the safety documents is anorexia (loss of appetite).

Q: Is Methicol recommended for people with a history of substance use?

A: Official regulatory labeling notes that the heavy or chronic intake of alcohol is documented to interfere with the intestinal absorption of Mecobalamin. General history of substance use is not specifically addressed in the same context.

Q: Can I take Methicol if I have a history of heart problems?

A: The official product labeling documents a risk of serious adverse reactions, including reports of Congestive Heart Failure and Peripheral Vascular Thrombosis (blood clots). This caution is documented due to the potential for cardiovascular events and should be considered in the context of any pre-existing heart problems.

Q: Can Methicol be taken with vitamins or herbal supplements?

A: The regulatory documents specifically note that taking Folic acid supplements can mask the blood signs of B₁₂ deficiency, allowing potential associated neurological issues to progress unaddressed. Other general vitamins and herbal supplements are not universally addressed in the labeling.

Q: How long do the effects of Methicol last after a dose?

A: The duration of effect is tied to the elimination rate of the substance from the body. Mecobalamin has a documented half-life ranging from approximately 6 to 24 hours. The specific time for the disappearance of the therapeutic effect for a single dose is not officially stated in the labeling.

Q: Can Methicol cause problems with vision?

A: Methicol is explicitly contraindicated (must not be used) for patients diagnosed with Leber's hereditary optic atrophy—a condition affecting the optic nerve. Vision problems are not typically listed as a common side effect for the general population.

How should Methicol be stored and disposed of?

How to Store and Dispose of Methicol?

Methicol (Mecobalamin) requires form-specific storage conditions to maintain stability, as mandated by regulatory authorities.

Storage Requirements

Form Temperature Requirement Additional Protection
Oral Tablets Store below 25 C (77 F) Protect from light and moisture. Keep container tightly closed.
Injection Solution Store refrigerated between 2 C and 8 C Do not freeze. Protect from light.

All forms must be kept in the original container and stored out of the sight and reach of children.

️ Disposal Instructions

Unused Methicol Injection Solution must be discarded immediately after the vial or ampoule is opened. To dispose of expired or unused medicine, utilize a drug take-back program. Do not dispose of Methicol by flushing it down the toilet or pouring it into a drain, as this violates official wastewater regulations. The medicine must not be used past its expiration date.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Methicol found in:

A-Z Index: